1. Introduction {#sec0001}
===============

Since its emergence in Wuhan, China in December 2019, a new coronavirus infection (COVID-19) due to a agent called SARS-CoV-2 spread rapidly worldwide, reaching more than more than 25 000 000 people as of August 30, 2020.

Most patients with multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMO-SD) are treated with disease modifying therapies (DMTs) either immunomodulators or immunosuppressants. DMTs target different types of immune cells, impacting differently cellular and/or humoral immunity. MS experts have proposed a stratification of the risk of acquiring severe COVID-19 infection ([@bib0001]), according to the immunodepletion related to DMTs.

However, beyond the effect of DMTs on the risk of COVID-19 infection, their potential effect on the long-term immune response against the coronavirus remains unknown. In this respect, compared to other DMTs, anti-CD20 therapies can impact immune response to infection or to vaccine due to their direct action on B cells ([@bib0003]). Three MS patients ([@bib0007]) ([@bib0008]) were recently reported with negative SARS-CoV-2 antibody testing following COVID-19 infection.

We report here the results of the SARS-CoV-2 serologic status of 13 MS and NMO-SD patients infected with COVID-19, which highlight that all patients on anti-CD20 therapies were seronegative.

2. Cases {#sec0002}
========

Patients were included in the French registry of COVID-19 in patients with MS or NMO-SD (NCT04355611, approval from the ethic committee of Sorbonne University \#CER-2020--19). The collection of non-opposition to the use of medical data was carried out according to French law, good clinical practice and GDPR.

We report SARS-CoV-2 serology for the first thirteen consecutive patients from Pitié-Salpêtrière Hospital, in Paris ([Table 1](#tbl0001){ref-type="table"} ): 7 female and 6 male, with median neurological disease duration of 17 years (range: 9--31). Twelve patients were on DMTs at the time of COVID-19 infection. Of the 5 patients on anti-CD20 therapy, one had a negative SARS-CoV-2 PCR, and one was not tested. Both patients were contact to people (wife or friend) diagnosed COVID-19 few days before, with positive SARS-CoV-2 PCR.Table 1Description of the cohort of MS/NMO-SD patients.Table 1:Age (years)Sex (M/F)DiagnosisEDSSCurrent DMTDuration on current DMT (months)Duration between last anti-CD20 administration and symptom onset (days)COVID-19 diagnosisSARS-Cov2 PCRSARS-Cov2 serology (IgG index)SARS-CoV2 serology techniqueDuration between COVID-19 clinical onset and SARS-COV2 serology (days)**Anti-CD20 DMTs**120FNMO-SD, AQP4+3ofatumumab31**10**Anosmia, astheniaPositiveNegativeAbbott59249MPPMS6rituximab13**59**Pneumonia, ground glass opacities on thoracic CT scan, hospitalized with supplemental oxygenPositiveNegativeAbbott46341MSPMS7rituximab30**132**Anosmia, ageusia, fever, coughNot done[\*](#tb1fn1){ref-type="table-fn"}NegativeBiosynex23455MPPMS3rituximab36**59**Pneumonia, ground glass opacities on thoracic CT scan, hospitalized with supplemental oxygenNegative[⁎⁎](#tb1fn2){ref-type="table-fn"}NegativeRoche65534FRRMS5.5ocrelizumab35**118**Pericarditis, pneumonia, ground glass opacities on thoracic CT scan, hospitalized with supplemental oxygenPositiveNegativeRoche64**DMTs other than anti-CD20**649FRRMS2teriflunomide53--Anosmia, ageusia, fever, cough, dyspneaNot donePositive (9,77)Abbott66738MRRMS2glatiramer4--Anosmia, ageusia, fever, dyspneaNot donePositive (7,97)Abbott51827FSPMS2glatiramer7--Anosmia, ageusia, fever, coughNot donePositive (4,86)Abbott54941MRRMS3dimethyl-fumarate66--Anosmia, ageusia, fever, cough, dyspneaNot donePositive (8,42)Abbott401039FRRMS1none----FeverPositivePositiveBiosynex321156FRRMS8natalizumab144--Pneumonia, ground glass opacities on thoracic CT scan, hospitalized with supplemental oxygenPositivePositive (8,52)Abbott681230FRRMS0natalizumab34--Anosmia, ageusia, fever, coughNot donePositive (2,19)Abbott761349MRRMS4dimethyl-fumarate72Pneumonia, ground glass opacities on thoracic CT scan, hospitalized with supplemental oxygenPositivePositive (6,8)Abbott71[^1][^2][^3][^4][^5][^6]

The median delay between COVID-19 symptoms onset and SARS-CoV-2 serology was 59 days (range: 23--76). SARS-CoV-2 serology was negative for the 5 patients treated by anti-CD20 antibodies. The median delay between the last administration of anti-CD20 therapy and the serology was 124 days (range: 69--180). In patients on anti-CD20 therapies, no hypogammaglobulinemia or lymphopenia was reported concomitantly in 3 patients, one patient had a grade 2 lymphopenia (740/mm^3^), and one patient had a severe grade 3 lymphopenia (370/mm^3^). When available (2/5), CD19 B-cells rate was low (0.03; 0.05%). Four patients were retested one month later: the SARS-CoV2 serology was still negative. For the 8 patients not treated by anti-CD20 DMTs, SARS-CoV-2 serology was positive. For the 7 patients with Abbott serology, the median IgG index was 7.97 (range: 2.19 - 9.77).

3. Discussion {#sec0003}
=============

We reported SARS-CoV-2 serology performed more than 3 weeks after COVID-19 infection in 13 patients with MS or NMO-SD. The serology was negative for all patients treated with monoclonal anti-CD20 antibodies.

CD20 is expressed at the surface of B-cells, from pre-B-cells stage to mature B-lymphocytes. B-cell depletion affects antibody production. In the HERMES study in MS ([@bib0002]), treatment with rituximab (RTX) was associated with rapid and near-complete depletion of CD19+ peripheral B-lymphocytes from 2 weeks after treatment until 24 weeks.

Several studies on vaccination (influenza, H1N1, pneumococcal vaccine) in patients with rheumatoid arthritis treated with RTX have been reported ([@bib0003]; [@bib0004]; [@bib0010]). IgM and IgG secretion was significantly decreased compared to patients treated with other immunosuppressant or healthy controls. It suggests that anti-CD20 therapy impairs the humoral response after these vaccines.

In a large cohort study of 285 patients with COVID-19 infection, all patients seroconverted between 17 and 19 days after symptom onset ([@bib0006]). In our case series, all patients had a SARS-CoV-2 serology, at least 23 days after symptoms onset. However, to date, in the general population, the immunogenicity against SARS-CoV-2 and the potential duration of this immunity are unknown. Moreover the potential for cross-reactivity with other coronaviruses (yielding false-positives) have to be determined ([@bib0005]).

The interpretation of SARS-CoV-2 serologies must be careful in patients with immunosuppressive therapies. The strategy regarding DMTs management in MS or NMO-SD might be hampered by the difficulties to retrospectively confirm COVID-19 especially on patients with anti-CD20 as in our cohort. Even if IgG index is very heterogeneous in the general population, it is striking that none of the 5 patients on anti-CD20 had a positive serology. If larger studies confirm that patients on anti-CD20 have a reduced or absent humoral response to COVID-19 infection, this could suggest that these patients may be more vulnerable to a re-infection, although data are lacking to conclude if presence of such antibodies might confer protection against re-infection. It is still unclear if impaired humoral response to SARS-CoV-2 due to anti-CD20 therapies might be responsible for more severe clinical forms of COVID-19 in the acute phase. First steps of immune response to SARS-CoV-2 mainly imply the innate immune system, including macrophages, innate lymphoid cells, followed by antiviral T cell response, while acute adaptive B cell response occurs later during the infection and is involved in virus clearance ([@bib0009]). If a vaccine against SARS-CoV-2 becomes available in the future, vaccination strategy will also be challenging for patients on anti-CD20 who previously developed COVID-19. To date, in the absence of long-term longitudinal studies, maximal precautions to prevent coronavirus infection, including social distancing and barrier measures, should be maintained even in MS/NMOSD patients who have already presented COVID-19 infection.
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[^1]: Abbott serology by chemiluminescent microparticulate immunoassays (index IgG positive: ≥1.4).

[^2]: Roche serology by electrochemiluminescence (ECLIA) on the Cobas® system (Roche Diagnostics, Bâle, Suisse) (index IgG positive : ≥1.0).

[^3]: Biosynex serology by immunochromatography (quick serologic test without IgG index quantification).

[^4]: Abbreviations: NMO-SD: neuromyelitis optica - spectrum disorders; AQP4: aquaporine 4; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis; PPMS: primary progressive multiple sclerosis; DMT disease modifying therapy; M: male; F: female.

[^5]: The patient\'s spouse had a diagnosis of COVID-19 confirmed by positive Sars-Cov2 PCR.

[^6]: COVID-19 diagnosis was confirmed on thoracic CT showing bilateral ground glass opacities. He reported a contact 3 days before symptoms onset with a friend who was confirmed of COVID-19 diagnosis by positive Sars-Cov2 PCR.
